Paroxysmal Nocturnal Hemoglobinuria News and Research

RSS
FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

New treatment for adults with rare, life-threatening blood disease receives FDA approval

New treatment for adults with rare, life-threatening blood disease receives FDA approval

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

Penn receives orphan status in Europe for treatment of PNH

Penn receives orphan status in Europe for treatment of PNH

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Penn research team discovers new cost-effective way to fight rare blood disorder

Penn research team discovers new cost-effective way to fight rare blood disorder

Penn researchers identify possible new way to fight rare blood disorder

Penn researchers identify possible new way to fight rare blood disorder

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Viropharma announces financial results for third quarter 2013

Viropharma announces financial results for third quarter 2013

Viropharma announces financial results for second quarter of 2013

Viropharma announces financial results for second quarter of 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases